Inhibition of NK-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis

Hiroshi Okamoto, Takuji Iwamoto, Shigeru Kotake, Shigeki Momohara, Hisashi Yamanaka, Naoyuki Kamatani

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Objectives: Inflammatory mediators such as interleukin-6 and tumor necrosis factor-α play an important role in the pathogenesis of rheumatoid arthritis (RA) by promoting chronic inflammation and joint damage. NF-κB is a transcriptional activator of genes for these cytokines. It also plays an important role in the regulation of osteoclast differentiation which plays a key role in joint destruction in RA. Ligands for peroxisome proliferator-activated receptor (PPAR) - γ have recently been reported to inhibit the development of RA. In this study, we investigated the role of PPARα in RA. Methods: We analyzed the protein expression of PPAR-α and -γ in rheumatoid synovial fibroblasts (RSF) from RA patients and analyzed the effects of ligands for PPAR-α and -γ on cytokine production from RSF, NF-κB activations in RSF and osteoclast differentiation from osteocalst progenitor in the peripheral blood. Moreover, we analyzed the effects of oral administration of PPAR-α and -γ ligands on the development of adjuvant-induced arthritis (AIA) in female Lewis rats. Results: We confirmed the expression of PPAR-α in RSF and also demonstrated that fenofibrate, a ligand for PPAR-α, inhibited cytokine production from RSF, NF-κB activation in RSF, and osteoclast differentiation from osteoclast progenitor cells. Furthermore, we demonstrated that fenofibrate inhibits the development of arthritis in a rat model of human RA. Conclusions: These results indicate that fenofibrate suppresses the development of arthritis by inhibition of NF-κB signaling; therefore, this compound offers possible anti-rheumatic drug.

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalClinical and Experimental Rheumatology
Volume23
Issue number3
Publication statusPublished - 2005 May
Externally publishedYes

Fingerprint

Fenofibrate
Peroxisome Proliferator-Activated Receptors
Rheumatoid Arthritis
Ligands
Fibroblasts
Osteoclasts
Cytokines
Therapeutics
Arthritis
Joints
Antirheumatic Agents
Experimental Arthritis
Oral Administration
Interleukin-6
Stem Cells
Tumor Necrosis Factor-alpha
Inflammation

Keywords

  • NF-κB
  • Peroxisome proliferator-activated receptor α
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Inhibition of NK-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis. / Okamoto, Hiroshi; Iwamoto, Takuji; Kotake, Shigeru; Momohara, Shigeki; Yamanaka, Hisashi; Kamatani, Naoyuki.

In: Clinical and Experimental Rheumatology, Vol. 23, No. 3, 05.2005, p. 323-330.

Research output: Contribution to journalArticle

@article{4e9b9c8c5aad4a0f9687edfd80b53022,
title = "Inhibition of NK-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis",
abstract = "Objectives: Inflammatory mediators such as interleukin-6 and tumor necrosis factor-α play an important role in the pathogenesis of rheumatoid arthritis (RA) by promoting chronic inflammation and joint damage. NF-κB is a transcriptional activator of genes for these cytokines. It also plays an important role in the regulation of osteoclast differentiation which plays a key role in joint destruction in RA. Ligands for peroxisome proliferator-activated receptor (PPAR) - γ have recently been reported to inhibit the development of RA. In this study, we investigated the role of PPARα in RA. Methods: We analyzed the protein expression of PPAR-α and -γ in rheumatoid synovial fibroblasts (RSF) from RA patients and analyzed the effects of ligands for PPAR-α and -γ on cytokine production from RSF, NF-κB activations in RSF and osteoclast differentiation from osteocalst progenitor in the peripheral blood. Moreover, we analyzed the effects of oral administration of PPAR-α and -γ ligands on the development of adjuvant-induced arthritis (AIA) in female Lewis rats. Results: We confirmed the expression of PPAR-α in RSF and also demonstrated that fenofibrate, a ligand for PPAR-α, inhibited cytokine production from RSF, NF-κB activation in RSF, and osteoclast differentiation from osteoclast progenitor cells. Furthermore, we demonstrated that fenofibrate inhibits the development of arthritis in a rat model of human RA. Conclusions: These results indicate that fenofibrate suppresses the development of arthritis by inhibition of NF-κB signaling; therefore, this compound offers possible anti-rheumatic drug.",
keywords = "NF-κB, Peroxisome proliferator-activated receptor α, Rheumatoid arthritis",
author = "Hiroshi Okamoto and Takuji Iwamoto and Shigeru Kotake and Shigeki Momohara and Hisashi Yamanaka and Naoyuki Kamatani",
year = "2005",
month = "5",
language = "English",
volume = "23",
pages = "323--330",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3",

}

TY - JOUR

T1 - Inhibition of NK-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis

AU - Okamoto, Hiroshi

AU - Iwamoto, Takuji

AU - Kotake, Shigeru

AU - Momohara, Shigeki

AU - Yamanaka, Hisashi

AU - Kamatani, Naoyuki

PY - 2005/5

Y1 - 2005/5

N2 - Objectives: Inflammatory mediators such as interleukin-6 and tumor necrosis factor-α play an important role in the pathogenesis of rheumatoid arthritis (RA) by promoting chronic inflammation and joint damage. NF-κB is a transcriptional activator of genes for these cytokines. It also plays an important role in the regulation of osteoclast differentiation which plays a key role in joint destruction in RA. Ligands for peroxisome proliferator-activated receptor (PPAR) - γ have recently been reported to inhibit the development of RA. In this study, we investigated the role of PPARα in RA. Methods: We analyzed the protein expression of PPAR-α and -γ in rheumatoid synovial fibroblasts (RSF) from RA patients and analyzed the effects of ligands for PPAR-α and -γ on cytokine production from RSF, NF-κB activations in RSF and osteoclast differentiation from osteocalst progenitor in the peripheral blood. Moreover, we analyzed the effects of oral administration of PPAR-α and -γ ligands on the development of adjuvant-induced arthritis (AIA) in female Lewis rats. Results: We confirmed the expression of PPAR-α in RSF and also demonstrated that fenofibrate, a ligand for PPAR-α, inhibited cytokine production from RSF, NF-κB activation in RSF, and osteoclast differentiation from osteoclast progenitor cells. Furthermore, we demonstrated that fenofibrate inhibits the development of arthritis in a rat model of human RA. Conclusions: These results indicate that fenofibrate suppresses the development of arthritis by inhibition of NF-κB signaling; therefore, this compound offers possible anti-rheumatic drug.

AB - Objectives: Inflammatory mediators such as interleukin-6 and tumor necrosis factor-α play an important role in the pathogenesis of rheumatoid arthritis (RA) by promoting chronic inflammation and joint damage. NF-κB is a transcriptional activator of genes for these cytokines. It also plays an important role in the regulation of osteoclast differentiation which plays a key role in joint destruction in RA. Ligands for peroxisome proliferator-activated receptor (PPAR) - γ have recently been reported to inhibit the development of RA. In this study, we investigated the role of PPARα in RA. Methods: We analyzed the protein expression of PPAR-α and -γ in rheumatoid synovial fibroblasts (RSF) from RA patients and analyzed the effects of ligands for PPAR-α and -γ on cytokine production from RSF, NF-κB activations in RSF and osteoclast differentiation from osteocalst progenitor in the peripheral blood. Moreover, we analyzed the effects of oral administration of PPAR-α and -γ ligands on the development of adjuvant-induced arthritis (AIA) in female Lewis rats. Results: We confirmed the expression of PPAR-α in RSF and also demonstrated that fenofibrate, a ligand for PPAR-α, inhibited cytokine production from RSF, NF-κB activation in RSF, and osteoclast differentiation from osteoclast progenitor cells. Furthermore, we demonstrated that fenofibrate inhibits the development of arthritis in a rat model of human RA. Conclusions: These results indicate that fenofibrate suppresses the development of arthritis by inhibition of NF-κB signaling; therefore, this compound offers possible anti-rheumatic drug.

KW - NF-κB

KW - Peroxisome proliferator-activated receptor α

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=20444440328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444440328&partnerID=8YFLogxK

M3 - Article

C2 - 15971419

AN - SCOPUS:20444440328

VL - 23

SP - 323

EP - 330

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3

ER -